All Columns articles
-
Opinion‘Molecular glues’ are sticking it to cancer
Compounds that enhance selected protein–protein interactions to interfere with signalling or send proteins to be destroyed are making it possible to influence processes that were previously considered ‘undruggable’
-
OpinionDeadly reminders of the importance of risk assessment
Serious incidents in two university labs highlight the importance of knowing what to do when things go wrong
-
OpinionOur cosmic origins remain plausible, not proven
The evidence is there that the molecular ingredients for life can form in space, but that doesn’t mean that they did
-
OpinionArtificial intelligence or clever artifice?
It’s important to be realistic about what AI can, and can’t, achieve, across the chemistry enterprise
-
OpinionMessy megamergers
Rumoured merger between AstraZeneca and Bristol Myers Squibb has collapsed, and that’s probably a good thing
-
OpinionTrump threatens generic drug tariffs
Plan aims to encourage domestic US supplies, but will it work?
-
OpinionWhere does chemical recycling of plastics go from here?
US and EU plant closures highlight economic difficulties of scaling technology alongside associated policy and infrastructure
-
OpinionTrust is easily broken and hard to rebuild
Thermo Fisher needs to be open and honest about data manipulation to reassure researchers
-
OpinionIs industry getting more or less safe?
US figures suggest an increase in incidents involving serious injuries and fatalities in recent years
-
OpinionShould the EU stop exports of pesticides it has banned?
Agrochemicals including paraquat remain legal elsewhere, prompting questions over regulatory responsibility
-
OpinionWhat kinds of reactions do you do most?
Variety may be the spice of life, but there’s space for the boring but effective
-
OpinionGSK agrees $10 billion deal for Nuvalent cancer drugs
Deal includes two late-stage molecules to augment GSK’s renewed cancer therapy pipeline
-
OpinionHow far will EU push for fairer trade with China?
Strengthening rules on pharmaceutical and chemical trade could protect critical industries
-
-
OpinionBritish Steel’s nationalisation plan contrasts against chemical industry decline
UK steel production has been declining for decades thanks to high costs and cheap imports
-
OpinionIran war’s global impact keeps growing
Shortages of bitumen, cooking gas and jet fuel are pushing up prices and disrupting construction
-
OpinionPurdue Pharma’s opioid prosecution enables bankruptcy settlement
$5 billion criminal sentence paves the way for resolution of civil liabilities through bankruptcy court
-
OpinionThe evolving landscape of pain drug discovery
Harnessing the power of human-relevant in vitro models
-
OpinionMajor drug regulators advancing routes to reduce animal testing
US, UK and EU all have goals to eliminate animal testing
-
OpinionIran ceasefire is the start of a long recovery process
Conflict’s impact on global energy and chemicals supply chains will take significantly longer to resolve